Summary. Most studies evaluating immune markers for prediction of Type i (insulin-dependent) diabetes mellitus have focused on first degree relatives, although only 10 % of newlydiagnosed patients have an affected first degree relative. The Swedish Childhood Diabetes Register identifies 99 % of all diabetic children at diagnosis. In this population-based study, islet cell antibodies and insulin autoantibodies in 0-14-yearold Swedish consecutively-diagnosed patients and control subjects were analysed to define their sensitivity and specificity. Over 16 months (1986)(1987), 515 Swedish children developed diabetes. Plasma samples were obtained from 494 (96 %) patients, and 420 matched control children. Among patients, the frequency of islet cell antibodies was 84 % (415 of 494), insulin autoantibodies 43 % (145 of 334); 40% (135 of 334) were positive for both and 88 % (294 of 334) were positive for one or both. Among control children, 3 % (14 of 420) had islet cell antibodies, 1% (4 of 390) insulin autoantibodies, and 4 % (16 of 390) had either autoantibody marker. The predictive value of finding a patient with the disease was only 7 % since 4 % of the control children were antibody-positive and the cumulative incidence rate up to 15 years of age is 0.38 %. None of the autoantibody-positive (n = 21) or negative control children developed diabetes during 3 to 5 years of follow-up. Longitudinal investigations of islet cell or insulinautoantibody-positive healthy children are necessary to accurately determine the conversion rate from marker positivity to disease onset.
Most studies on the role of autoimmune markers in the pathogenesis of Type 1 (insulin-dependent) diabetes mellitus have focused on first degree relatives. Although the risk for T~e 1 diabetes is increased among relatives, and many of them may have a reduced acute insulin response to glucose [1, 2] , subclinical Beta-cell dysfunction which does not progress to clinical Type 1 diabetes appears to be common [2, 3] . Islet cell (cytoplasmic) antibodies (ICA) [4, 5] and insulin autoantibodies (IAA) [6] are often detected both before and at the time of clinical onset [7] . The ICA [5] and IAA [8] assays have recently been standardized to allow levels to be expressed in common units and valid comparisons can now be made between laboratories screening for diabetes. A possible relationship between ICA or IAA and loss of Beta-cell function has been demonstrated both in newly-diagnosed patients [9, 10] and in selected first degree relatives of Type I diabetic patients [11] [12] [13] . Recent prospective studies carried out over 5-11 years on more than 6000 first degree relatives [2, [14] [15] [16] ] demonstrated a higher frequency of ICA (3-10%) than of Type 1 diabetes (0.5-2 %), and suggest that ICA may occur transiently. To avoid ascertainment and recruitment bias, patient registries [17] [18] [19] and populationbased studies are increasingly important in defining markers for Type 1 diabetes in children who are not relatives to Type 1 diabetic patients.
In the present study, we have determined ICA and IAA levels in consecutive newly-diagnosed Type 1 diabetic children and compared the prevalence and levels with those found in population-based control children to define sensitivity, specificity and predictive value of these markers alone or in combination for Type 1 diabetes. In addition to a population-based design, this study represents the largest number of recent-onset diabetic children ever tested for both ICA and IAA. We have also followedup a similar number of healthy children for up to 5 years to determine if any of them have developed Type I diabetes.
Subjects, materials and methods
All 0-14-year-old children who develop Type 1 diabetes in Sweden are admitted to one of the country's 44 paediatric departments. Newly-diagnosed patients are reported to the Swedish Childhood Diabetes Register at a 99 % level of ascertainment [17, [20] [21] [22] . The present paper reports the second study of patients and control children, performed between 1 September 1986-31 December 1987. During these 16 months blood samples were obtained from 494 (96 %) of 515 consecutively-registered patients. The median age of the patients was 9 years, with a range of 1-14 years. The male to female ratio was 1.08 (256: 238). The date of diagnosis was defined as the day when the first insulin injection was given. In 355 of 494 patients (72 %) the blood sample was obtained either before or within 5 days after the initiation of insulin therapy and plasma for IAA was available from 334 of 355 of these patients. IAA were not determined on patients treated for 5 days or longer (n = 139) to exclude the possibility of detecting antibodies to exogenous insulin. We also tested whether the 139 patients treated with insulin for 5 days or longer introduced a sampling error, but the frequency and levels of ICA, age, gender, geographical and seasonal variation in this group did not differ from the 334 patients who were included in the analysis of IAA. The control group (n = 423) was recruited from two sources. For ethical reasons, blood samples from control children below 7 years of age (n = 52, or 12% of the control subjects) were obtained from children who had been subjected to venepuncture at a paediatric department for reasons other than diabetes or other endocrine or infectious diseases. The second group of control children (n = 371, or 88 % of the control subjects) were 7-14-year-old children selected from the general population as described in detail [17, 23] using the civic registration number of the Swedish Population Register to identify a control child born the same day, of the same gender and in the same county. For each of the 359 7-14-year-old patients, two control children (n = 718) were invited to participate in the study of whom 371 (52 %) volunteered. The entire control group comprised 423 children aged 1-15-years, median age 11 years and a male to female ratio of 1.05 (217 of 206). It took a median of 6 weeks to receive the blood sample from the control children after the registration of a Type I diabetic patient. The control children and their families were informed that the purpose of the study was a health survey without specific mention of diabetes to avoid a selection bias. For ethical reasons, blood was drawn only once from the control children and they have not been contacted for additional tests. During 3 to 5 years of follow-up, the possible development of Type i diabetes among control children was monitored continuously through the Swedish Childhood Diabetes Register and the Swedish Diabetes Register for Young Adults. At the first check, three control children (3 of 423) were determined as having already been registered as Type 1 diabetic patients in 1983,1984 and 1987, respectively. These three individuals were therefore excluded as control children but their data on ICA and IAA are included to illustrate the ability of these markers to identify children who are already diabetic in the background population of 0-14-year-olds. When remaining control children were found to be positive for ICA or IAA or both, the paediatric departments in their region were contacted to determine whether Type i diabetes had been previously diagnosed.
Informed consent was obtained from all parents and children. The study was approved by the Swedish Data Inspection Board and by the Ethical Committee at the Karotinska Institute, Stockholm, Sweden.
Islet cell and insulin autoantibodies
Venepuncture was performed to collect 10 ml EDTA blood samples which were sent from the local hospital, or for control children, from community health care clinics to our laboratory in Malm6 (Sweden) where the samples were centrifuged, plasma aliquoted and stored at -80 °C until further analysis. ICA were analysed in Malm6 in an indirect two-colour immunofluorescence assay using frozen human pancreas of blood group 0 as described in detail [24] [25] [26] . Only one pancreas was used throughout the study. Coded slides were evaluated by at least two independent observers. Each assay included internal negative and positive standards in diffcrent dilutions. The samples were titrated in 1:2, 1:4, 1 : 8, etc., dilutions, and the end point titre was defined as the highest titre of detectable ICA. The levels are expressed in Juvenile Diabetes Foundation (JDF) units by constructing a linear regression line between multiple end point titres of different dilutions [26] from the international reference serum [5] . The SD of the internal positive standard sample showed a variation of 1.0 titration steps, corresponding to a coefficient of variation of 15 %. The Maim0 ICA laboratory participates in the JDF-sponsored international diabetes workshops and proficiency testing programs. The lower detection limit for our assay is 1 JDF uult.
IAA were measured in Seattle (Washington, USA) using a radiobinding assay as previously described [6, 27] and displacement with cold insulin as stipulated by the international workshop on standardization of IAA [8] . Since this assay does not distinguish between insulin antibodies formed in response to exogenous insulin administration and IAA, only the 334 patients who had been treated with insulin for 5 days or less were evaluated. The cut-off level between positive and negative values was 2.3 %, defined as the 99th percentile of the percem binding among the 420 non-diabetic control children.
Statistical analysis
Values are given as median, range and quartile deviation if not normally distributed, and mean, range and SD if normally distributed. Differences in frequencies and levels of autoantibodies were tested with the chi square and the Mann-Whitney U-test, respectively. The Spearman rank correlation analysis (r~) was used to test correlations between levels of antibodies and age. Two-tailed probabiIity (p) value of 0.05 was considered to indicate statistical significance. Predictive values were calculated from the formula: Pxc~ predictive value = Pxo~+(1-P) x(t- [3) where P is prevalence, in Sweden determined to be 0.15 % in 0-14-year-olds [20] , c~ is sensitivity (positivity in disease) and 13 is specificity (negativity in health). 
Results
The prevalence of ICA (Fig. 1) was 415 of 494, or 84% among the newly-diagnosed Type 1 diabetic children (Fig. 1,A) . The range of ICA was 3-26,500 JDF units, and the median level was 57 JDF units among ICA positive Type 1 patients. The frequency of ICA positive control subjects was 14 of 420, or 3 % (Fig. 1, C) . The levels of ICA ranged between 5-200 JDF units, and the median level was 17 JDF units in ICA positive control children. The median level of ICA in the patients (57 JDF units) was not significantly different from the control subjects (17 JDF units). The levels of ICA in the three control children found to be already registered as Type 1 diabetic patients (Fig. 2) were 9, 26 and 110 JDF units, respectively.
IAA were analysed in 334 newly-diagnosed Type 1 diabetic children who had received insulin for 5 days or less. IAA have previously not been analysed in a childhood population and the control children were used to establish a normal range (Fig. 2D) . IAA binding in the newty-diagnosedType 1 diabeticpatients ranged from0.9-50.3 % ;the median percent binding was 20 % (Fig. 2 C) . The control subjects defined the cut-off limit for the 99th percentile as greater than 2.3 %, hence 1% (4 of 390) were IAA positive, with a range 3.6-6.2 % binding. Using this cut-off level, IAA were present in 43 % of the patients. The three control children already reported to the Diabetes Register (Fig. 2 D) , had been treated with insulin for 7 months, 3 and 4 years, respectively. Accordingly, their high level of percent binding is most likely explained by the presence of insulin antibodies, and not IAA.
We then analysed the extent to which ICA were related to IAA and to other epidemiological features of Type 1 diabetes such as age, gender, geographical location and seasonal variation. In patients, ICA ( Fig.2A) and IAA (Fig. 2 C) showed a weak but significant negative correlation with age (rs = -0.1,p < 0.02 and r~ = -0.4,p < 0.001, respectively). ICA levels correlated to IAA (rs=0.3; p < 0.001) (Fig. 3 A) . There was no effect of gender, geographical location or season of diagnosis on the frequency or levels of ICA or IAA (data not shown).
The frequency of patients positive for ICA or IAA or both was 88 % (294 of 334), with 40 % (135 of 334) positive for both. In 390 control children analysed for both ICA and IAA, 4 % (16 of 390) were positive for ICA or IAA; no non-diabetic control child was positive for both autoantibodies (Fig. 3) .
The sensitivity, specificity and predictive values for ICA and IAA alone or in combination are summarized in Table 1 . It should be noted that these predictive values are an indication of the ability of the test to find a patient with undiagnosed Type 1 diabetes in the general population. The positive predictive value for Type i diabetes following a positive screen needs to be determined in longitudinal studies. ICA and IAA alone had high specificity (97-99%), but, the low prevalence (0.15%) or cumulative incidence rate (0.38 % ) of Type 1 diabetes in the general Swedish childhood population [20, 22] resulted in predictive values varying between 4 and 14 %. Positivity of ICA IAA or both increased the sensitivity, but the predictive value remained low (3 % and 7 % respectively). Positivity for both autoantibodies was not found in any of the con- geographically matched control children (B). Three children ([~]) positive for both ICA and IAA were already registered in the Swedish Childhood Diabetes Register diagnosed with Type i diabetes, and were therefore excluded as control subjects trol children, but fewer than half of all diabetic patients (40 %) would be detected using this criterion ( Table 1) . The Swedish Diabetes Register has been monitored during a 3 to 5 year follow-up period for the possible registration of a diagnosis of Type 1 diabetes for the 420 control children who participated in this case-control study. As of March 1992, none of the 18 antibody-positive, nor any of the negative control children have been registered. It is projected that 14,815 children will have to be followed-up for 5 years to detect 20 diabetic patients (Table 2) .
Discussion
A variety of antibodies against islet cells [4, 6, 9, [28] [29] [30] [31] [32] are used as markers for autoimmune destruction of the pancreatic Beta cells, but these may not be pathognomonic since they sometimes occur transiently without progression to Type i diabetes [23] . Prospective family studies initiated more than 10 years ago, however, have also revealed that ICA might be present long before the clinical onset of the disease [13, 33] . These initial studies of ICA were confirmed and extended to IAA [13, [34] [35] [36] but usually in highly selected first degree relatives. The conversion rate from marker positivity to clinical Type 1 diabetes is variable for the different autoantibodies [2, 3, 14] . First-degree relatives do not seem to reflect the majority of the 0-14-year-old group who develop diabetes. A fundamental step in population-based investigations of Type i diabetes markers is to determine their sensitivity, specificity and predictive value [23] . The ICA levels in our previous [23] and present studies were remarkably similar. Together, the two studies report a total of 886 newly-diagnosed 0-14-year-old Type i diabetic patients. Nevertheless, some children develop Type 1 diabetes without being positive for either IAA or ICA; in this investigation we found that 40 (12 %) of the new patients did not have either marker. All of these 40 children have remained on insulin therapy. It is possible that some patients might have had ICA levels below our detection limit of 1 JDF unit or that they became negative before onset.
The selection of the control group is the most critical step in accurately determining specificity for ICA or IAA or both, and is a serious weakness in many published studies. The Swedish Population Register made it possible for us to select two control children of the same gender, born the same day and living in the same county as the patient. Furthermore, Type i diabetes was not specifically mentioned in the recruitment of control children, which reduced the risk for bias towards relatives of diabetic patients. Three children were identified with Type 1 diabetes by comparing the civic registration numbers of all control children against the Swedish Childhood Diabetes Register, illustrating the utility of the Register.
The frequency of ICA among the control children was 3 %, equal to our previous study [23] . Since the prevalence of Type I diabetes among 0-14-year-olds in Sweden is 0.15 % [20] , it is a provocative finding that the ICA frequency exceeds the disease prevalence by a factor of 20. Prior to the standardization of the ICA assay, the frequency of ICA among control subjects was generally reported as 0.1-1%. After the introduction of ICA standardization and the JDF standard serum, frequencies of 4% in 1218 Finnish school children [37] , 2.2% in 540 healthy children from the United Kingdom and blood donors [15] , and 1.7 % in 7740 French schoolchildren [38] were reported, supporting the hypothesis that ICA in the background population exceeds the prevalence of the disease.
The ICA levels in the 14 control children positive in this study did not differ from the median ICA level of the Type i diabetic patients (17 compared to 57 JDF units, 20 100 100,000 27 135 The above estimates are based on an annual incidence rate of 27 per 100,000 0-14.99 year olds NS). It has been concluded from family studies [14, 15] that ICA of 20 or less JDF units is rarely associated with progression to Type 1 diabetes. This cut-off limit for ICA would result in a sensitivity of 79 %, specificity would be 98 % and predictive value 5 %, hence, our result would not be changed.
Taking our two studies together, beginning in September 1985 through December 1987, we have studied a total of 741 healthy Swedish children. The longest follow-up is 6 years in these children. In the first year, two out of nine ICA-positive children developed Type i diabetes [23] . So far, none of the other ICA (n = 21) or IAA (n = 4) positive nor any negative control children have been registered as Type 1 diabetic patients. None of the controls was positive for both ICA and IAA in the present study. Therefore, if we had found one control subject positive for both, 1 of 390 or 0.3 %, the specificity would be 99.7 % and the positive predictive value would decrease from 100 % ( Table 1) to 17 %. These calculations demonstrate that a large number of healthy children need to be tested (Table 2) and followed longitudinally to accurately estimate the positive predictive value for Type 1 diabetes. If the entry criterion for intervention trials were single antibody positivity, our study shows that the frequency of false positives would be too high to make such trials ethical [39] . Our study suggests that future studies should measure both ICA and IAA and use a Beta-cell function test [2, 3] to refine the ability to predict and thus prevent Type 1 diabetes.
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